Welcome to our dedicated page for NuSkin Enterprises news (Ticker: NUS), a resource for investors and traders seeking the latest updates and insights on NuSkin Enterprises stock.
Nu Skin Enterprises, Inc. reports developments tied to its beauty and wellness business, affiliate opportunity platform and international market operations. Company updates commonly cover quarterly revenue and earnings, customer, paid affiliate and sales leader trends, dividend declarations, cost discipline and product commercialization across Nu Skin personal care, Pharmanex nutrition and ageLOC anti-aging brands.
Recurring news also includes the rollout of Prysm iO, an intelligent wellness platform that uses skin scans to provide antioxidant-related insights, and activity at Rhyz, the company’s strategic investment arm for consumer, technology and manufacturing businesses in beauty, wellness and lifestyle categories. Leadership appointments and operating-structure changes are also part of the company’s public updates.
Nu Skin Enterprises (NYSE: NUS) appointed Chelsea Lantz as interim Chief Financial Officer, effective March 20, 2026, after James Thomas stepped down to pursue an outside opportunity. The board has started a formal search for a permanent CFO while Lantz will continue cost-improvement and operational performance efforts.
Lantz joined Nu Skin in 2011, served as corporate controller since 2023, and led initiatives that the company says produced a significant year-over-year increase in EPS. She previously worked at PricewaterhouseCoopers and holds a Master of Accounting from Utah State University.
Nu Skin (NYSE:NUS) appointed Chayce Clark as chief operating officer, effective March 9, 2026, while he retains his chief legal officer role.
Clark will lead revenue performance and end-to-end operations, overseeing global sales, product innovation, technology platforms, brand programs and legal services across nearly 50 markets, and will support the Prysm iO rollout and India expansion.
Nu Skin (NYSE: NUS) reported Q4 2025 revenue of $370.3M (down 16.9%) and full-year 2025 revenue of $1.49B (down 14.3%). Fiscal 2025 EPS was $3.18 with more than 50% earnings growth year-over-year. Q4 gross margin improved to 70.7% and operating margin was 6.3%.
The company provided Q1 2026 revenue guidance of $320–$340M and full-year 2026 revenue guidance of $1.35–$1.50B with EPS of $0.80–$1.20. Management highlighted Prysm iO device rollout and India pre-market work as growth initiatives.
Nu Skin Enterprises (NYSE: NUS) declared a quarterly cash dividend of $0.06 per share. The dividend is payable on Mar. 11, 2026 to shareholders of record on Feb. 27, 2026.
This notice communicates the declared per-share amount, record date, and payment date for investors.
Nu Skin (NYSE: NUS) announced the relaunch of Dr. Joseph Chang’s bestselling book The Aging Myth with 15 years of additional research on measurable biology and cellular wellness.
The updated edition links expanded chapters on cellular resilience, oxidative stress, and measurable biomarkers to Nu Skin’s Prysm iO platform and ageLOC technologies. The digital edition is available today for $9.99 on major retailers.
Stonegate Capital Partners attended the ICR 2026 conference in Dallas on January 14, 2026, where it moderated a fireside chat with Nu Skin (NASDAQ: NUS). Stonegate also attended presentations from LifeVantage (LFVN), USANA (USNA), Beachbody (BODI) and Strauss Group (STRS), and observed an RSM panel on "cutting through the AI hype." The release notes common themes across retail, hybrid and DTC go-to-market models in nutrition, beauty and wellness sectors and points readers to the full announcement for images and bios.
Nu Skin Enterprises (NYSE:NUS) will release its fourth quarter and full year 2025 financial results after the market closes on Thursday, Feb. 12, 2026. The management team will host a conference call the same day at 5:00 p.m. ET to discuss recent results and upcoming business initiatives. A live webcast of the call and the financial presentation will be available on the company investor relations site at ir.nuskin.com. A replay will remain available through Thursday, Feb. 26, 2026.
Nu Skin (NYSE: NUS) announced that president and CEO Ryan Napierski will participate in a moderated fireside chat at the ICR Conference on Monday, Jan. 12, 2026 to discuss company strategy and the state of the business. The discussion will cover 2026 plans to launch the Prysm iO intelligent wellness device and growth opportunities in emerging markets, including India. The event will be webcast live at 1:30 p.m. ET, with an archive available on the company investor relations site through Monday, Jan. 26, 2026.
Nu Skin (NYSE: NUS) released its 2024 Social Impact and Sustainability Report outlining philanthropy and environmental progress. Highlights include $4.6 million donated globally, 1,400 children's heart surgeries performed in 2024 (part of >32,000 since 1999), and 30 million meals purchased and donated through Nourish the Children in 2024 (totaling >850 million since 2002).
On sustainability, Nu Skin reports reducing 8.5 tons of plastic and 1.4 tons of paper, using >24 tons of recycled plastic and 100% RSPO sourcing for palm ingredients, and a goal to make all product packaging recycled, recyclable, reusable, reduced or renewable by 2030. The company received 37 awards for sustainability and social impact.
Nu Skin (NYSE: NUS) launched Prysm iO, an AI-powered, portable skin-scanning platform that measures carotenoid antioxidant levels via a finger scan and delivers a personalized Prysm Score. Built on 20+ years of carotenoid research and a database of >21 million scans, Prysm iO uses patent-pending Spectral Rai Technology and AI algorithms. A Nu Skin randomized, double-blind, placebo-controlled study (n=46) reported 43–46% skin carotenoid increases over 12 weeks and serum increases of 44% vitamin C and 26% selenium. Device rollout: qualified brand representatives in Q4 2025, broader consumer availability in early to mid-2026.